Science ❯ Biology ❯ Neuroscience

Immunology

Vaccinology Vaccine Development Oncology

Biohaven Investors Face Sept. 12 Deadline in Securities Class Action

The Connecticut case claims the company misled the market on the prospects of two key drug programs.

UNM Launches Phase 1a/1b Trial of Tau-Targeting Alzheimer’s Vaccine